Trifarotene

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris in those nine years of age and older.[1] It is a retinoid;[2] more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.[3]

Trifarotene

Clinical data
Trade names	Aklief
Other names	CD5789
AHFS/Drugs.com	Monograph
MedlinePlus	a620004
License data	US DailyMed: Trifarotene
Pregnancy category	AU: D
Routes of administration	Topical
Drug class	Skin and mucous membrane agents
ATC code	D10AD06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only
Identifiers
IUPAC name 4-[3-(3-tert-Butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
CAS Number	895542-09-3
PubChem CID	11518241
DrugBank	DB12808
ChemSpider	9693029
UNII	0J8RN2W0HK
KEGG	D11225
ChEMBL	ChEMBL3707313
CompTox Dashboard (EPA)	DTXSID30237781
ECHA InfoCard	100.278.901
Chemical and physical data
Formula	C29H33NO4
Molar mass	459.586 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
InChI InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33) Key:MFBCDACCJCDGBA-UHFFFAOYSA-N

It was approved for medical use in the United States in 2019,[1][4][5] but is not approved in the European Union as of January 2021.[6] Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[7][8]

References

1. "Drug Trials Snapshots: Aklief". U.S. Food and Drug Administration (FDA). 11 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
2. Trifarotene Monograph
3. Scott LJ (November 2019). "Trifarotene: First Approval". Drugs. 79 (17): 1905–1909. doi:10.1007/s40265-019-01218-6. PMID 31713811.
4. "Aklief (trifarotene) FDA Approval History". Drugs.com. 7 October 2019. Retrieved 19 November 2019.
5. "Drug Approval Package: Aklief". U.S. Food and Drug Administration (FDA). 21 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.
6. "Trifarotene". European Medicines Agency. Retrieved 17 June 2020.
7. "Trifarotene Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 19 August 2020.
8. "EU/3/20/2264". European Medicines Agency (EMA). 12 August 2020. Retrieved 19 August 2020.

External links

• "Trifarotene". Drug Information Portal. U.S. National Library of Medicine (NLM).